Journal article
Primary HPV DNA based cervical cancer screening at 25 years: Views of young Australian women aged 16-28 years
Y Jayasinghe, C Rangiah, A Gorelik, G Ogilvie, JD Wark, S Hartley, SM Garland
Journal of Clinical Virology | Published : 2016
Abstract
Background: Revised Australian guidelines have been announced under the Renew® program to commence screening at 25 years of age with HPV testing in 5-yearly intervals, in 2017. We conducted a study of young Victorian women to assess attitudes towards a change in cervical screening practice. Methods: An online survey was conducted of young women aged 16-28 years enrolled in the Young Female Health Initiative (YFHI) study at the Royal Women's Hospital, Melbourne, to assess attitudes towards delaying the age of cervical screening, widening screening intervals and screening with HPV DNA testing, prior to the announcement of the renewal. Results: Of 149 respondents (response rate 75%), mean age w..
View full abstractGrants
Funding Acknowledgements
None declared. YJ has received scholarship funding from the Cancer Council Victoria, Royal Australian and New Zealand College of Obstetricians and Gynaecologists, and Royal Australasian Chapter of Sexual Health Medicine (Novartis Scholarship) and grant funding from the Victorian Cancer Agency and Victorian Comprehensive Cancer Network for unrelated projects. SG has received grant support from CSL Bio, Merck and GlaxoSmithKline to conduct HPV vaccine studies (VIVIANNE) trial. SG is a member of the Merck Global Advisory Board as well as the Merck Scientific Advisory Committee for HPV (unpaid position).